Research progress of DPYD gene variation in colorectal cancer
10.3760/cma.j.issn.1006-9801.2014.03.021
- VernacularTitle:结直肠癌中DPYD基因变异的研究进展
- Author:
Yunlu TAO
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms;
Gene,DPYD;
Gene variation;
Drug therapy
- From:
Cancer Research and Clinic
2014;26(3):206-209
- CountryChina
- Language:Chinese
-
Abstract:
5-fluorouracil (5-Fu) as the most common adjuvant chemotherapy has been widely used for patients with colorectal cancer.As reported dihydropyrimidine dehydrogenase (DPD) has been known as an initial rate-limiting enzyme to catalyze approximately 80 ％ of administered dose of 5-Fu.However,patients with a partial or complete DPD deficiency because of the mutation of DPYD gene may suffer from diarrhea,stomatitis,hand-foot syndrome or neurotoxicity and even death.In this article,the application of DPYD gene screening in patients with colorectal cancer of current status and recent clinical application are reviewed.
